XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Inventory | 9 Months Ended
--- | ---
Sep. 30, 2016
Inventory |
(4) | Inventory
The Company capitalizes its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories as of September 30, 2016 and December 31, 2015 consist of the following:
In thousands |  | September 30, 2016 |  |  | December 31, 2015 |
Raw materials |  | $ | 8,926 |  |  | $ | 9,096 |
Work in process |  |  | 7,579 |  |  |  | 1,640 |
Finished goods |  |  | 3,268 |  |  |  | 8,249 |
Total inventory |  | $ | 19,773 |  |  | $ | 18,985 |

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration